Reproducibility of repeated breathhold and impact of breathhold failure in whole breast and regional nodal irradiation in prone crawl position.
Adult
Aged
Breath Holding
Dose Fractionation, Radiation
Feasibility Studies
Female
Humans
Lymph Nodes
/ diagnostic imaging
Lymphatic Metastasis
Middle Aged
Organs at Risk
/ radiation effects
Patient Positioning
/ adverse effects
Prone Position
Radiotherapy Planning, Computer-Assisted
/ adverse effects
Radiotherapy, Adjuvant
Tomography, X-Ray Computed
Treatment Outcome
Unilateral Breast Neoplasms
/ diagnostic imaging
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
03 02 2022
03 02 2022
Historique:
received:
02
02
2021
accepted:
20
01
2022
entrez:
4
2
2022
pubmed:
5
2
2022
medline:
11
3
2022
Statut:
epublish
Résumé
In whole breast and regional nodal irradiation (WB + RNI), breathhold increases organ at risk (OAR) sparing. WB + RNI is usually performed in supine position, because positioning materials obstruct beam paths in prone position. Recent advancements allow prone WB + RNI (pWB + RNI) with increased sparing of OARs compared to supine WB + RNI. We evaluate positional and dosimetrical impact of repeated breathhold (RBH) and failure to breathhold (FTBH) in pWB + RNI. Twenty left-sided breast cancer patients were scanned twice in breathhold (baseline and RBH) and once free breathing (i.e. FTBH). Positional impact was evaluated using overlap index (OI) and Dice similarity coefficient (DSC). Dosimetrical impact was assessed by beam transposition from the baseline plan. Mean OI and DSC ranges were 0.01-0.98 and 0.01-0.92 for FTBH, and 0.73-1 and 0.69-1 for RBH. Dosimetric impact of RBH was negligible. FTBH significantly decreased minimal dose to CTV WBI, level II and the internal mammary nodes, with adequate mean doses. FTBH significantly increased heart, LAD, left lung and esophagus dose. OI and DSC for RBH and FTBH show reproducible large ROI positions. Small ROIs show poor overlap. FTBH maintained adequate target coverage but increased heart, LAD, ipsilateral lung and esophagus dose. RBH is a robust technique in pWB + RNI. (Clinicaltrials.gov: NCT05179161, registered 05/01/2022).
Identifiants
pubmed: 35115610
doi: 10.1038/s41598-022-05957-7
pii: 10.1038/s41598-022-05957-7
pmc: PMC8814154
doi:
Banques de données
ClinicalTrials.gov
['NCT05179161']
Types de publication
Clinical Trial
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1887Informations de copyright
© 2022. The Author(s).
Références
Br J Radiol. 2021 Jun 1;94(1122):20210079
pubmed: 33914612
Acad Radiol. 2004 Feb;11(2):178-89
pubmed: 14974593
Radiat Oncol. 2015 Jan 09;10:9
pubmed: 25572707
Radiother Oncol. 2015 Jan;114(1):3-10
pubmed: 25630428
Radiother Oncol. 2015 Dec;117(3):473-6
pubmed: 26455452
J Med Imaging Radiat Oncol. 2012 Jun;56(3):362-7
pubmed: 22697337
Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):10-8
pubmed: 20421148
N Engl J Med. 2015 Jul 23;373(4):307-16
pubmed: 26200977
Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):263-269
pubmed: 29066123
J Clin Oncol. 2016 Feb 1;34(4):314-20
pubmed: 26598752
Radiother Oncol. 2016 Jan;118(1):209-10
pubmed: 26743831
Radiother Oncol. 2007 Mar;82(3):341-8
pubmed: 17207547
JAMA. 2012 Sep 5;308(9):861-3
pubmed: 22948692
Radiother Oncol. 2016 Jan;118(1):205-8
pubmed: 26791404
Radiother Oncol. 2015 Jan;114(1):11-6
pubmed: 25466373
Radiat Oncol. 2015 Sep 22;10:200
pubmed: 26391237
Strahlenther Onkol. 2019 Jan;195(1):13-20
pubmed: 30143814
Lancet Oncol. 2014 Nov;15(12):1303-10
pubmed: 25439688
Radiother Oncol. 2020 Jan;142:195-201
pubmed: 31540747
Med Dosim. 2017 Autumn;42(3):185-189
pubmed: 28579017
Radiother Oncol. 2012 Jan;102(1):74-81
pubmed: 21993404
Clin Oncol (R Coll Radiol). 2017 Mar;29(3):e51-e56
pubmed: 27890346
Lancet Oncol. 2020 Dec;21(12):1602-1610
pubmed: 33152277
Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):2055-64
pubmed: 21570208
Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):33-9
pubmed: 16542789
Pract Radiat Oncol. 2016 Jul-Aug;6(4):e81-e88
pubmed: 26723552
Medicine (Baltimore). 2021 May 21;100(20):e26000
pubmed: 34011096
Sci Rep. 2019 Mar 18;9(1):4755
pubmed: 30894606
Radiat Oncol. 2017 May 26;12(1):89
pubmed: 28549483
Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):745-51
pubmed: 18687534
J Appl Clin Med Phys. 2017 Jul;18(4):200-205
pubmed: 28649708
Radiother Oncol. 2013 Jan;106(1):28-32
pubmed: 23199652
Radiother Oncol. 2011 Aug;100(2):221-6
pubmed: 21159397
Int J Radiat Oncol Biol Phys. 2012 Nov 15;84(4):902-9
pubmed: 22494590
Am J Clin Oncol. 2011 Jun;34(3):223-30
pubmed: 20562590
Radiat Oncol. 2015 Dec 21;10:258
pubmed: 26691175
Br J Radiol. 2012 Oct;85(1018):e899-905
pubmed: 22457317
Sci Rep. 2021 Mar 16;11(1):6085
pubmed: 33727599
Radiat Oncol. 2019 Dec 10;14(1):223
pubmed: 31822293
N Engl J Med. 2013 Mar 14;368(11):987-98
pubmed: 23484825
Radiother Oncol. 2015 Jan;114(1):79-84
pubmed: 25497557